Utility of Mutant Drosophila to Develop Therapies for Mitochondrial Diseases

Description

University of Pittsburgh researchers have identified a novel mutation in the endogenous Drosophila mitochondrial ATP6 gene which conferes neuromuscular impairment. There are several known human diseases, namely NARP, MILS and FBSN, that result form mutation of the ATP6 gene. Our mutation represents, to our knowledge, the first known isolated mitochondrial mutation in an animal system. Because of the paralysis, behavioral and degenerative phenotypes of these animals, they could be used to screen for therapeutic targets or directly to screen for therapeutic compounds in vivo.

IP Status

Research Tool

Quick Facts:
Reference Number
01079
Technology Type
Life Science Research Tool
Technology Subtype
Animal Model
Therapeutic Areas
Endocrinology and Metabolic Diseases
Therapeutic Indications
Mitochondrial Disease
Lead Inventor
Michael Palladino
Department
Med-Pharmacology and Chemical Biology
All Tech Innovators
Alicia M. CelottoMichael John Palladino
Date Submitted
2005-03-30
Collections
Cardiometabolic